Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology.

ESC Committee for Practice Guidelines (CPG), Silvia G. Priori (Chairperson) (Italy), Jean-Jacques Blanc (France), Andrzej Budaj (Poland), John Camm (UK), Veronica Dean (France), Jaap Deckers (The Netherlands), Kenneth Dickstein (Norway), John Lekakis (Greece), Keith McGregor (France), Marco Metra (Italy), Joao Morais (Portugal), Ady Osterspey (Germany), Juan Tamargo (Spain), Jose Luis Zamorano (Spain)
 Document Reviewers, Marco Metra (CPG Review Coordinator) (Italy), Michael Bohm (Germany), Alain Cohen-Solal (France), Martin Cowie (UK), Ulf Dahlstrom (Sweden), Kenneth Dickstein (Norway), Gerasimos S. Filippatos (Greece), Edoardo Gronda (Italy), Richard Hobbs (UK), John K. Kjekshus (Norway), John McMurray (UK), Lars Ryden (Sweden), Gianfranco Sinagra (Italy), Juan Tamargo (Spain), Michal Tendera (Poland), Dirk van Veldhuisen (The Netherlands), Faiez Zannad (France) Guidelines and Expert Consensus Documents aim to present all the relevant evidence on a particular issue in order to help physicians to weigh the benefits and risks of a particular diagnostic or therapeutic procedure. They should be helpful in everyday clinical decision-making. A great number of Guidelines and Expert Consensus Documents have been issued in recent years by the European Society of Cardiology (ESC) and by different organizations and other related societies. This profusion can put at stake the authority and validity of guidelines, which can only be guaranteed if they have been developed by an unquestionable decision-making process. This is one of the reasons why the ESC and others have issued recommendations for formulating and issuing Guidelines and Expert Consensus Documents. In spite of the fact that standards for issuing good quality Guidelines and Expert Consensus Documents are well defined, recent surveys of Guidelines and Expert Consensus Documents published in peer-reviewed journals between 1985 and 1998 have shown that methodological standards were not complied with in the vast majority of cases. It is therefore of great importance that guidelines and recommendations are presented in formats that are …

[1]  R. Maestri,et al.  Short-Term Heart Rate Variability Strongly Predicts Sudden Cardiac Death in Chronic Heart Failure Patients , 2003, Circulation.

[2]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[3]  J. McMurray,et al.  Do patients with suspected heart failure and preserved left ventricular systolic function suffer from “diastolic heart failure” or from misdiagnosis? A prospective descriptive study , 2000, BMJ : British Medical Journal.

[4]  P A Poole-Wilson,et al.  The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. , 2004, American heart journal.

[5]  M. Pfeffer,et al.  Left Ventricular Remodeling and Ventricular Arrhythmias After Myocardial Infarction , 2003, Circulation.

[6]  J R Wilson,et al.  Value of Peak Exercise Oxygen Consumption for Optimal Timing of Cardiac Transplantation in Ambulatory Patients With Heart Failure , 1991, Circulation.

[7]  H. Abu‐Saad,et al.  Effects of education and support on self-care and resource utilization in patients with heart failure. , 1999, European heart journal.

[8]  M. Drazner,et al.  Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. , 2001, Journal of the American College of Cardiology.

[9]  N. Awan,et al.  A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Irbesartan Heart Failure Group. , 2000, International journal of clinical practice.

[10]  A Hofman,et al.  Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. , 1999, European heart journal.

[11]  L. Levin,et al.  Nurse-led heart failure clinics improve survival and self-care behaviour in patients with heart failure: results from a prospective, randomised trial. , 2003, European heart journal.

[12]  Gabrielli,et al.  Determination of candidacy for mechanical circulatory support: importance of clinical indices , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[13]  Ralph D'Agostino,et al.  Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. , 2004, The New England journal of medicine.

[14]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[15]  G. Fonarow,et al.  Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. , 2002, Journal of the American College of Cardiology.

[16]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[17]  P. Ponikowski,et al.  Uric Acid and Survival in Chronic Heart Failure: Validation and Application in Metabolic, Functional, and Hemodynamic Staging , 2003, Circulation.

[18]  G A Ewy,et al.  Bedside cardiovascular examination in patients with severe chronic heart failure: importance of rest or inducible jugular venous distension. , 1993, Journal of the American College of Cardiology.

[19]  J. Cleland,et al.  Systematic review of the management of atrial fibrillation in patients with heart failure. , 2000, European heart journal.

[20]  J. Steiner,et al.  Heart failure with preserved left ventricular systolic function , 2003 .

[21]  T. Killip,et al.  Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. , 1967, The American journal of cardiology.

[22]  S. Hohnloser,et al.  Usefulness of microvolt T-wave alternans for prediction of ventricular tachyarrhythmic events in patients with dilated cardiomyopathy: results from a prospective observational study. , 2003, Journal of the American College of Cardiology.

[23]  M. Keller,et al.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. , 1997, The New England journal of medicine.

[24]  Bertram Pitt,et al.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.

[25]  W. Remme.  The treatment of heart failure. Task Force of the Working Group on Heart Failure of the European Society of Cardiology. , 1997, European heart journal.

[26]  M. Pfeffer,et al.  Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure—Assessment of Reduction in Mortality and morbidity (CHARM) programme , 2003, European journal of heart failure.

[27]  Thierry C. Gillebert,et al.  How to diagnose diastolic heart failure , 1998 .

[28]  J. Cohn,et al.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.

[29]  G. C. Carlson,et al.  The treatment of heart failure. , 1949, The Mississippi doctor.

[30]  J. Cohn,et al.  Prognostic Significance of Serial Changes in Left Ventricular Ejection Fraction in Patients With Congestive Heart Failure , 1993, Circulation.

[31]  F. Tristani,et al.  Ejection Fraction, Peak Exercise Oxygen Consumption, Cardiothoracic Ratio, Ventricular Arrhythmias, and Plasma Norepinephrine as Determinants of Prognosis in Heart Failure , 1993, Circulation.

[32]  R. Prescott,et al.  Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). , 1998, Circulation.

[33]  U. Khot,et al.  Prognostic importance of physical examination for heart failure in non-St-elevation acute coronary syndromes the enduring value of Killip classification , 2004 .

[34]  L. Stevenson,et al.  The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. , 1989, JAMA.

[35]  J. Cleland,et al.  The heart failure epidemic: exactly how big is it? , 2001, European heart journal.

[36]  G. Kay,et al.  Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials. , 2004, Journal of the American College of Cardiology.

[37]  L. Tavazzi,et al.  Peak exercise oxygen consumption in chronic heart failure: toward efficient use in the individual patient. , 1998, Journal of the American College of Cardiology.

[38]  Michael V. Green,et al.  Verapamil-induced improvement in left ventricular diastolic filling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short- and long-term effects. , 1985, Circulation.

[39]  N. Freemantle,et al.  Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEM , 2003, European journal of heart failure.

[40]  C. Cipolla,et al.  Hemofiltration as short-term treatment for refractory congestive heart failure. , 1987, The American journal of medicine.

[41]  H. C. Kim,et al.  Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. , 1997, Journal of the American College of Cardiology.

[42]  P. Weissberg,et al.  Coronary artery calcification , 2000 .

[43]  A. Coats,et al.  Life-Years Gained From Defibrillator Implantation: Markedly Nonlinear Increase During 3 Years of Follow-Up and Its Implications , 2004, Circulation.

[44]  A. Weyman,et al.  Analysis of the early transmitral Doppler velocity curve: effect of primary physiologic changes and compensatory preload adjustment. , 1990, Journal of the American College of Cardiology.

[45]  A. Connor,et al.  The way I see it: House officers need formal career development , 2002 .

[46]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[47]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[48]  G. Breithardt,et al.  [Task Force on Sudden Cardiac Death, European Society of Cardiology. Summary of recommendations]. , 2002, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[49]  L. Tavazzi,et al.  Loading manipulations improve the prognostic value of Doppler evaluation of mitral flow in patients with chronic heart failure. , 1997, Circulation.

[50]  M. Janse,et al.  Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials , 1997, The Lancet.

[51]  B. Simon,et al.  Comparison of the effect of sucralfate and ranitidine in reflux esophagitis. , 1987, The American journal of medicine.

[52]  D. Fukai,et al.  Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. , 1997, Circulation.

[53]  U Ravens,et al.  Task Force on Sudden Cardiac Death of the European Society of Cardiology. , 2001, European heart journal.

[54]  A. Moss,et al.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. , 1996, The New England journal of medicine.

[55]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[56]  J. Cleland,et al.  Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial , 2002, The Lancet.

[57]  M. Domanski,et al.  A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. , 2001, The New England journal of medicine.

[58]  Alan S Maisel,et al.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.

[59]  D. Delurgio,et al.  Cardiac resynchronization in chronic heart failure. , 2002, The New England journal of medicine.

[60]  S. Hunt.  Heart failure overview. , 2004, The Journal of thoracic and cardiovascular surgery.

[61]  J. Cohn,et al.  Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. , 1997, Circulation.

[62]  R. Prescott,et al.  Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. , 2002, Journal of the American College of Cardiology.

[63]  H. Dargie,et al.  Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.

[64]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[65]  E. Trulock,et al.  Worldwide thoracic organ transplantation: a report from the UNOS/ISHLT International Registry for Thoracic Organ Transplantation. , 2000, Clinical transplants.

[66]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure , 1986 .

[67]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[68]  H. Denolin,et al.  The defintion of heart failure , 1983 .

[69]  N. Hollenberg,et al.  Literature alert , 2002 .

[70]  Simon Stewart,et al.  Effects of a multidisciplinary, home-based intervention on planned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study , 1999, The Lancet.

[71]  N. Freemantle,et al.  Clinical trials update and cumulative meta‐analyses from the American College of Cardiology: WATCH, SCD‐HeFT, DINAMIT, CASINO, INSPIRE, STRATUS‐US, RIO‐Lipids and cardiac resynchronisation therapy in heart failure , 2004, European journal of heart failure.

[72]  How to diagnose diastolic heart failure. European Study Group on Diastolic Heart Failure. , 1998, European heart journal.

[73]  Hugh Tunstall-Pedoe,et al.  Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population , 1997, The Lancet.

[74]  J P Wexler,et al.  The relationship between left ventricular systolic function and congestive heart failure diagnosed by clinical criteria. , 1988, Circulation.

[75]  G. Sutton,et al.  Objective assessment of the response to treatment of severe heart failure using a 9-minute walk test on a patient-powered treadmill. , 1996, Journal of cardiac failure.

[76]  J. Schwartz,et al.  Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. , 1996, Circulation.

[77]  T. Cheng.  Definition of heart failure. , 1999, European journal of heart failure.

[78]  C. T. Layton,et al.  Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia , 1996 .

[79]  R. McKelvie,et al.  Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy : the randomized evaluation of strategies for left ventricular dysfunction pilot study. , 2000, Circulation.

[80]  F. Tristani,et al.  Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure. Results of a Veterans Administration Cooperative Study , 1987 .

[81]  G. Murray,et al.  Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators , 1993 .

[82]  K. Swedberg,et al.  Guidelines for the diagnosis and treatment of chronic heart failure. , 2001, European heart journal.

[83]  B. Radovancević,et al.  Prolonged QTc Interval and High B-Type Natriuretic Peptide Levels Together Predict Mortality in Patients With Advanced Heart Failure , 2003, Circulation.

[84]  James C Moon,et al.  Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. , 2004, American heart journal.

[85]  J. Cleland,et al.  Increased alveolar/capillary membrane resistance to gas transfer in patients with chronic heart failure. , 1994, British heart journal.

[86]  L. Stevenson,et al.  Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. , 2003, Journal of the American College of Cardiology.

[87]  M. Pfeffer,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.

[88]  L. Tavazzi,et al.  Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. , 2001, Journal of the American College of Cardiology.

[89]  M. A. Plant.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality , 1991 .

[90]  J. McMurray,et al.  Trends in hospitalization for heart failure in Scotland 1980-1990. , 1993, European heart journal.

[91]  J. Polak,et al.  Right ventricular ejection fraction: an indicator of increased mortality in patients with congestive heart failure associated with coronary artery disease. , 1983, Journal of the American College of Cardiology.

[92]  Bittner,et al.  Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. , 1993, JAMA.

[93]  P. Poole‐Wilson,et al.  Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. , 1987, British heart journal.

[94]  Luigi Tavazzi,et al.  Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure. , 2002, American heart journal.

[95]  T. Dormans,et al.  Chronic intermittent haemofiltration and haemodialysis in end stage chronic heart failure with oedema refractory to high dose frusemide. , 1996, Heart.

[96]  M. Emdin,et al.  The Circulating Levels of Cardiac Natriuretic Hormones in Healthy Adults: Effects of Age and Sex , 2002, Clinical chemistry and laboratory medicine.

[97]  Luigi Tavazzi,et al.  Recommendations for exercise testing in chronic heart failure patients. , 2001, European heart journal.

[98]  G. Steinbeck,et al.  A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic, sustained ventricular tachyarrhythmias. , 1992, The New England journal of medicine.

[99]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[100]  L. Tavazzi,et al.  Reproducibility of the six-minute walking test in patients with chronic congestive heart failure: practical implications. , 1998, The American journal of cardiology.

[101]  J. McMurray,et al.  Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. , 2004, Journal of the American College of Cardiology.

[102]  T. R. I. Nvestigators.  A TRIAL OF THE BETA-BLOCKER BUCINDOLOL IN PATIENTS WITH ADVANCED CHRONIC HEART FAILURE , 2001 .

[103]  H. Black,et al.  Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. , 1990, The American journal of cardiology.

[104]  P. Poole‐Wilson,et al.  Factors determining symptoms in heart failure: comparison of fast and slow exercise tests. , 1986, British heart journal.

[105]  C. O'connor,et al.  A standardized definition of ischemic cardiomyopathy for use in clinical research. , 2002, Journal of the American College of Cardiology.

[106]  P. Wood.  Diseases of the Heart and Circulation , 1902, The Hospital.

[107]  R. Collins,et al.  Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review , 2002, The Lancet.

[108]  J. Remes,et al.  Validity of clinical diagnosis of heart failure in primary health care. , 1991, European heart journal.

[109]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[110]  M. Pfeffer,et al.  Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. , 2003, Journal of the American College of Cardiology.

[111]  V. Fuster,et al.  ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conference , 2001, Circulation.

[112]  Australia..  Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease , 1997, The Lancet.

[113]  P. Ponikowski,et al.  Enhanced Ventilatory Response to Exercise in Patients With Chronic Heart Failure and Preserved Exercise Tolerance: Marker of Abnormal Cardiorespiratory Reflex Control and Predictor of Poor Prognosis , 2001, Circulation.

[114]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[115]  C. Friedberg.  DISEASES OF THE HEART , 1933, The Ulster Medical Journal.

[116]  Hugh Calkins,et al.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. , 2004, The New England journal of medicine.

[117]  S. Yusuf,et al.  Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study , 2003, The Lancet.

[118]  E. Aliot,et al.  A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. , 1995, The New England journal of medicine.

[119]  P. Dunselman.  Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) investigators. , 2001, International journal of cardiology.

[120]  H. Joller-jemelka,et al.  Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. , 2003, Journal of the American College of Cardiology.

[121]  S. Silver,et al.  Heart Failure , 1937, The New England journal of medicine.

[122]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[123]  T. MacDonald,et al.  Echocardiography in chronic heart failure in the community. , 1993, The Quarterly journal of medicine.

[124]  Abdissa Negassa,et al.  Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study , 2003, The Lancet.

[125]  M. Rich.  Heart failure disease management: a critical review. , 1999, Journal of cardiac failure.

[126]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[127]  Robert J Cody,et al.  Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction. , 2002, American heart journal.

[128]  Salim Yusuf,et al.  Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients , 2000, The Lancet.

[129]  M. Pfeffer,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both , 2004 .

[130]  N Freemantle,et al.  The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. , 2003, European heart journal.

[131]  B. Pitt,et al.  Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[132]  R. McKelvie,et al.  Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. , 2002, Journal of the American College of Cardiology.

[133]  A. Mansur,et al.  Periodic breathing during incremental exercise predicts mortality in patients with chronic heart failure evaluated for cardiac transplantation. , 2003, Journal of the American College of Cardiology.

[134]  E. Trulock,et al.  Worldwide thoracic organ transplantation: a report from the UNOS/ISHLT international registry for thoracic organ transplantation. , 2001, Clinical transplants.

[135]  M. Weinberger,et al.  Does increased access to primary care reduce hospital readmissions? Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission. , 1996, The New England journal of medicine.

[136]  D. Murdoch,et al.  ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects. , 2001, American heart journal.

[137]  S. Goodman,et al.  Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. , 2003, JAMA.

[138]  William J. Rogers,et al.  Prediction of Mortality and Morbidity With a 6-Minute Walk Test in Patients With Left Ventricular Dysfunction , 1993 .

[139]  W. Rogers,et al.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. , 1989, The New England journal of medicine.

[140]  B. Brendorp,et al.  Long-term survival in patients hospitalized with congestive heart failure: relation to preserved and reduced left ventricular systolic function. , 2003, European heart journal.

[141]  B. Fagerberg,et al.  Feasibility of a nurse-monitored, outpatient-care programme for elderly patients with moderate-to-severe, chronic heart failure. , 1998, European heart journal.

[142]  Akshay S. Desai,et al.  Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. , 2005, JAMA.

[143]  P. Giannuzzi,et al.  Ventilatory response to exercise improves risk stratification in patients with chronic heart failure and intermediate functional capacity. , 2002, American heart journal.

[144]  M. Pfeffer,et al.  Effects of long-term treatment with angiotensin-converting enzyme inhibitors in the presence or absence of aspirin: A systematic review ☆ , 2003 .

[145]  Thomas Lavergne,et al.  Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. , 2002, Journal of the American College of Cardiology.

[146]  K. Swedberg,et al.  Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. , 2004, Journal of the American College of Cardiology.

[147]  P A Poole-Wilson,et al.  Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. , 1999, Circulation.

[148]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[149]  D. DeMets,et al.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.

[150]  L. Tavazzi,et al.  Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry). , 2002, American heart journal.

[151]  M. Domanski,et al.  The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. , 2000, Journal of the American College of Cardiology.

[152]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[153]  J. Cleland,et al.  Clinical trials update: OPTIME‐CHF, PRAISE‐2, ALL‐HAT , 2000, European journal of heart failure.

[154]  D. Levy,et al.  Natural History of Asymptomatic Left Ventricular Systolic Dysfunction in the Community , 2003, Circulation.

[155]  H. Hense,et al.  Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population , 2000, Journal of hypertension.

[156]  K. Lee,et al.  A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. , 1999, The New England journal of medicine.

[157]  J. Cleland,et al.  Is the prognosis of heart failure improving? , 1999, Journal of the American College of Cardiology.

[158]  G. Sinagra,et al.  Persistence of restrictive left ventricular filling pattern in dilated cardiomyopathy: an ominous prognostic sign. , 1997, Journal of the American College of Cardiology.

[159]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[160]  P C Deedwania,et al.  Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. , 1995, The New England journal of medicine.

[161]  J. McMurray,et al.  It cannot be cardiac failure because the heart is not enlarged on the chest X‐ray , 2003, European journal of heart failure.

[162]  K. Dickstein,et al.  [Executive summary of the guidelines on the diagnosis and treatment of acute heart failure]. , 2005, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[163]  R. Falk,et al.  Should all patients with atrial fibrillation receive warfarin? Evidence from randomized clinical trials. , 1996, European heart journal.

[164]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[165]  D J Pennell,et al.  Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. , 2000, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[166]  M C Oz,et al.  Long-term use of a left ventricular assist device for end-stage heart failure. , 2001, The New England journal of medicine.

[167]  F. Zannad,et al.  Clinical definition and epidemiology of advanced heart failure. , 1998, American heart journal.

[168]  Milton Packer,et al.  Cardiac resynchronization in chronic heart failure. , 2002, The New England journal of medicine.

[169]  S. Yusuf,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-alternative trial , 2004 .

[170]  F. Turnbull.  Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials , 2003, The Lancet.

[171]  Akshay S. Desai,et al.  Implantable Defibrillators for the Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-analysis of Randomized Controlled Trials , 2004 .

[172]  P. Ponikowski,et al.  Wasting as independent risk factor for mortality in chronic heart failure , 1997, The Lancet.

[173]  J. Daubert,et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.

[174]  A. Camm,et al.  Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. , 1999, The New England journal of medicine.

[175]  S. Jauhar,et al.  The Economics of ICDs. , 2004, The New England journal of medicine.

[176]  J. Cohn,et al.  Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. , 2002, Journal of the American College of Cardiology.

[177]  S. Stewart,et al.  Effects of a home-based intervention among patients with congestive heart failure discharged from acute hospital care. , 1998, Archives of internal medicine.

[178]  A. Cohen-Solal,et al.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). , 2005, European heart journal.

[179]  U. Janssens,et al.  Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism. , 2004, American heart journal.

[180]  S. Lévy,et al.  Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. , 1998, European heart journal.

[181]  K. Swedberg,et al.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. , 1990, Circulation.

[182]  C. Yancy.  Does race matter in heart failure? , 2003, American heart journal.

[183]  K. Swedberg,et al.  [Expert Consensus document on beta-adrenergic receptor blockers]. , 2004, Revista espanola de cardiologia.

[184]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[185]  P. Armstrong,et al.  Randomised trials of secondary prevention programmes in coronary heart disease: systematic review , 2001, BMJ : British Medical Journal.

[186]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.

[187]  E. Topol,et al.  Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification. , 2003, JAMA.

[188]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.